기관지폐 이형성 시장 : 시장 규모 - 약제 유형별, 치료 유형별, 최종 사용자별, 지역별 분석 및 예측(2022-2032년)

The Global Bronchopulmonary Dysplasia Market, valued at approximately USD 385.6 billion in 2023, is poised to expand at a compound annual growth rate (CAGR) of 6.1% during the forecast period 2024-2032. Bronchopulmonary dysplasia (BPD), a serious lung condition primarily affecting premature infants, has driven the development of advanced therapeutic solutions. The market's growth is underpinned by innovations in treatment protocols, spanning from drug therapies to cutting-edge regenerative methods like stem cell therapy. As healthcare infrastructure evolves globally, the demand for BPD-related drugs and therapies continues to rise.

The escalating prevalence of premature births and advancements in neonatal care are critical drivers augmenting the market's expansion. Sophisticated therapeutic approaches, such as nitric oxide therapy and surfactant homeostasis treatments, have revolutionized patient outcomes, addressing the complex needs of infants suffering from BPD. However, the high costs associated with advanced therapies and challenges in regulatory compliance pose significant barriers. Nonetheless, emerging opportunities in research and development (R&D), coupled with government initiatives to enhance neonatal care facilities, are likely to bolster the market's growth trajectory.

North America leads the global market, driven by robust healthcare infrastructure, increased funding for pediatric research, and the rapid adoption of innovative therapeutic solutions. Europe follows closely, benefiting from stringent healthcare regulations and substantial investments in clinical trials. The Asia-Pacific region is expected to witness the fastest growth, supported by rising healthcare expenditures in countries such as China and India, and growing awareness about neonatal disorders. Moreover, markets in Latin America and the Middle East & Africa are gaining momentum due to infrastructural advancements and increased focus on addressing unmet healthcare needs.

As the bronchopulmonary dysplasia market evolves, industry players are investing heavily in R&D to develop novel therapeutic approaches. Collaboration between biopharmaceutical companies and healthcare institutions is fostering innovation, while advancements in personalized medicine and data analytics are streamlining treatment efficacy. The integration of cutting-edge technologies is set to transform the BPD therapeutic landscape, paving the way for enhanced patient outcomes and market sustainability.

Major market players included in this report are:

• Thermo Fisher Scientific Inc.
• Lonza Group AG
• STEMCELL Technologies Inc.
• Merck KGaA
• Fujifilm Cellular Dynamics Inc.
• Cellular Biomedicine Group Inc.
• Takara Bio Inc.
• Sartorius AG
• Bluebird Bio Inc.
• Pluristem Therapeutics Inc.
• Bio-Rad Laboratories Inc.
• Promega Corporation
• Novartis AG
• Corning Incorporated
• Miltenyi Biotec

The detailed segments and sub-segments of the market are explained below:

By Drug Type:

• Bronchodilators
• Diuretics
• Antibiotics
• Steroids
• Immunomodulators
• Surfactant Homeostasis

By Therapy Type:

• Nitric Oxide Therapy
• Protein Replacement Therapy
• Stem Cell Therapy
• Supplemental Oxygen

By End User:

• Hospitals
• Nursing Homes
• Critical Care Centres

By Region: North America:

• U.S.
• Canada

Europe:

• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific:

• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia-Pacific

Latin America:

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa:

• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:

• Historical Year: 2022
• Base Year: 2023
• Forecast Period: 2024 to 2032

Key Takeaways:

• Market estimates and forecasts for 10 years from 2022 to 2032.
• Annualized revenues and regional-level analysis for each market segment.
• Comprehensive geographical insights with country-level analysis for major regions.
• Competitive landscape profiling major market players and their strategic initiatives.
• Analysis of key business strategies and recommendations for future market approaches.

Table of Contents

Chapter 1. Global Bronchopulmonary Dysplasia Market Executive Summary

• 1.1. Global Bronchopulmonary Dysplasia Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Drug Type
    • 1.3.1.1. Bronchodilators
    • 1.3.1.2. Diuretics
    • 1.3.1.3. Antibiotics
    • 1.3.1.4. Steroids
    • 1.3.1.5. Immunomodulators
    • 1.3.1.6. Surfactant Homeostasis
  • 1.3.2. By Therapy Type
    • 1.3.2.1. Nitric Oxide Therapy
    • 1.3.2.2. Protein Replacement Therapy
    • 1.3.2.3. Stem Cell Therapy
    • 1.3.2.4. Supplemental Oxygen
  • 1.3.3. By End User
    • 1.3.3.1. Hospitals
    • 1.3.3.2. Nursing Homes
    • 1.3.3.3. Critical Care Centres
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Bronchopulmonary Dysplasia Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Consumer's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory Frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Consumer Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Bronchopulmonary Dysplasia Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Escalating Prevalence of Premature Births
  • 3.1.2. Advancements in Neonatal Care
  • 3.1.3. Innovative Therapeutic Approaches
• 3.2. Market Challenges
  • 3.2.1. High Costs of Advanced Therapies
  • 3.2.2. Regulatory Compliance Difficulties
• 3.3. Market Opportunities
  • 3.3.1. Expansion in Research and Development (R&D)
  • 3.3.2. Government Initiatives Enhancing Neonatal Care Facilities
  • 3.3.3. Adoption of Personalized Medicine and Data Analytics

Chapter 4. Global Bronchopulmonary Dysplasia Market Industry Analysis

• 4.1. Porter's 5 Force Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's 5 Force Model
  • 4.1.7. Porter's 5 Force Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunities
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspective
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Bronchopulmonary Dysplasia Market Size & Forecasts by Drug Type 2022-2032

• 5.1. Segment Dashboard
• 5.2. Global Bronchopulmonary Dysplasia Market: Drug Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 5.2.1. Bronchodilators
  • 5.2.2. Diuretics
  • 5.2.3. Antibiotics
  • 5.2.4. Steroids
  • 5.2.5. Immunomodulators
  • 5.2.6. Surfactant Homeostasis

Chapter 6. Global Bronchopulmonary Dysplasia Market Size & Forecasts by Therapy Type 2022-2032

• 6.1. Segment Dashboard
• 6.2. Global Bronchopulmonary Dysplasia Market: Therapy Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 6.2.1. Nitric Oxide Therapy
  • 6.2.2. Protein Replacement Therapy
  • 6.2.3. Stem Cell Therapy
  • 6.2.4. Supplemental Oxygen

Chapter 7. Global Bronchopulmonary Dysplasia Market Size & Forecasts by End User 2022-2032

• 7.1. Segment Dashboard
• 7.2. Global Bronchopulmonary Dysplasia Market: End User Revenue Trend Analysis, 2022 & 2032 (USD Billion)
  • 7.2.1. Hospitals
  • 7.2.2. Nursing Homes
  • 7.2.3. Critical Care Centres

Chapter 8. Global Bronchopulmonary Dysplasia Market Size & Forecasts by Region 2022-2032

• 8.1. North America Bronchopulmonary Dysplasia Market
  • 8.1.1. U.S. Bronchopulmonary Dysplasia Market
    • 8.1.1.1. Drug Type Breakdown Size & Forecasts, 2022-2032
    • 8.1.1.2. Therapy Type Breakdown Size & Forecasts, 2022-2032
    • 8.1.1.3. End User Breakdown Size & Forecasts, 2022-2032
  • 8.1.2. Canada Bronchopulmonary Dysplasia Market
    • 8.1.2.1. Drug Type Breakdown Size & Forecasts, 2022-2032
    • 8.1.2.2. Therapy Type Breakdown Size & Forecasts, 2022-2032
    • 8.1.2.3. End User Breakdown Size & Forecasts, 2022-2032
• 8.2. Europe Bronchopulmonary Dysplasia Market
  • 8.2.1. UK Bronchopulmonary Dysplasia Market
  • 8.2.2. Germany Bronchopulmonary Dysplasia Market
  • 8.2.3. France Bronchopulmonary Dysplasia Market
  • 8.2.4. Spain Bronchopulmonary Dysplasia Market
  • 8.2.5. Italy Bronchopulmonary Dysplasia Market
  • 8.2.6. Rest of Europe Bronchopulmonary Dysplasia Market
• 8.3. Asia-Pacific Bronchopulmonary Dysplasia Market
  • 8.3.1. China Bronchopulmonary Dysplasia Market
  • 8.3.2. India Bronchopulmonary Dysplasia Market
  • 8.3.3. Japan Bronchopulmonary Dysplasia Market
  • 8.3.4. Australia Bronchopulmonary Dysplasia Market
  • 8.3.5. South Korea Bronchopulmonary Dysplasia Market
  • 8.3.6. Rest of Asia-Pacific Bronchopulmonary Dysplasia Market
• 8.4. Latin America Bronchopulmonary Dysplasia Market
  • 8.4.1. Brazil Bronchopulmonary Dysplasia Market
  • 8.4.2. Mexico Bronchopulmonary Dysplasia Market
  • 8.4.3. Rest of Latin America Bronchopulmonary Dysplasia Market
• 8.5. Middle East & Africa Bronchopulmonary Dysplasia Market
  • 8.5.1. Saudi Arabia Bronchopulmonary Dysplasia Market
  • 8.5.2. South Africa Bronchopulmonary Dysplasia Market
  • 8.5.3. Rest of Middle East & Africa Bronchopulmonary Dysplasia Market

Chapter 9. Competitive Intelligence

• 9.1. Key Company SWOT Analysis
  • 9.1.1. Thermo Fisher Scientific Inc.
  • 9.1.2. Lonza Group AG
  • 9.1.3. STEMCELL Technologies Inc.
• 9.2. Top Market Strategies
• 9.3. Company Profiles
  • 9.3.1. Thermo Fisher Scientific Inc.
    • 9.3.1.1. Key Information
    • 9.3.1.2. Overview
    • 9.3.1.3. Financial (Subject to Data Availability)
    • 9.3.1.4. Product Summary
    • 9.3.1.5. Market Strategies
  • 9.3.2. Lonza Group AG
  • 9.3.3. STEMCELL Technologies Inc.
  • 9.3.4. Merck KGaA
  • 9.3.5. Fujifilm Cellular Dynamics Inc.
  • 9.3.6. Cellular Biomedicine Group Inc.
  • 9.3.7. Takara Bio Inc.
  • 9.3.8. Sartorius AG
  • 9.3.9. Bluebird Bio Inc.
  • 9.3.10. Pluristem Therapeutics Inc.
  • 9.3.11. Bio-Rad Laboratories Inc.
  • 9.3.12. Promega Corporation
  • 9.3.13. Novartis AG
  • 9.3.14. Corning Incorporated
  • 9.3.15. Miltenyi Biotec

Chapter 10. Research Process

• 10.1. Research Process
  • 10.1.1. Data Mining
  • 10.1.2. Analysis
  • 10.1.3. Market Estimation
  • 10.1.4. Validation
  • 10.1.5. Publishing
• 10.2. Research Attributes